PDCD1 and cancer: RT+anti-CD47/anti-SIRPα+anti-PD-1 antibodies triple therapy was found to induce vigorous systemic antitumor immunity based on the induction of TAA-specific CD8+ T cell priming by DCs and the initiation of CD8+ T cell expansion and activation.25 More interestingly, studies have shown that only under the premise of DAMPs released by cancer cells after RT, SIRPα-deficient macrophages can obtain a strong ability to present TAAs to T cells.25,115